SEHK:6855Biotechs
Ascentage Pharma Group International (SEHK:6855) Deep TTM Loss Challenges Bullish Growth Narrative
Ascentage Pharma Group International (SEHK:6855) has just posted its FY 2025 first half results, with revenue of C¥233.7 million and a basic EPS loss of C¥1.73, setting a cautious tone around earnings quality. Over recent periods, the company has reported revenue of C¥823.7 million in 1H 2024, C¥156.9 million in 2H 2024, and C¥233.7 million in 1H 2025, while basic EPS has moved from a profit of C¥0.56 in 1H 2024 to losses of C¥1.82 in 2H 2024 and C¥1.73 in 1H 2025. For investors, the focus is...